Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The company said it will present two posters on its deupirfenidone program at the IPF Summit in Boston on Sept. 29-Oct. 1, 2026. It said SURPASS-IPF is a global Phase 3 head-to-head trial of deupirfenidone versus pirfenidone in about 1,100 adults with idiopathic pulmonary fibrosis.
Celea Therapeutics, Inc. ("Celea" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for serious respiratory diseases with significant unmet medical need, today announced that the Company will deliver two poster presentations showcasing its…